CNS Metastases clinical trials at UCSD

1 research study open to eligible people

IAM1363 in HER2 Cancers
open to eligible people ages 18 years and up
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
La Jolla, California and other locations

Last updated: December 16, 2025